ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: () Report Updated: Jun 17, 2013 | Print This Page

Get more stock ratings by Louis Navellier

(BMTI)

Rating: Volatility:
Total Grade: Industry:
Competitors:
hide

Stock Analysis

Rating: Monthly View

A
B
C
D
F
June July August September October November December January February March April May

Rating: Weekly View

This Week: down no change
Last Week: same no change
Two Weeks Ago: up no change
service keys
hide

© quotemedia

hide

Company Profile

BioMimetic Therapeutics, Inc., a biotechnology company, engages in the development and commercialization of regenerative protein therapeutic products primarily used for bone and tissue regeneration, repair and healing of musculoskeletal injuries, and conditions affecting bones, tendons, ligaments, and cartilage. The company’s orthopedic products include Augment Bone Graft for open fracture and fusion treatment; and Augment Injectable Bone Graft for open or closed fracture treatment and minimally invasive fracture/fusion treatment. Its products also comprise Augment Rotator Cuff Graft for rotator cuff tendon to bone repair; Augment OCD for cartilage and bone repair; TBD for the treatment of injuries due to tendon overuse; and Augment Bone Graft for spine fusion. The company was formerly known as BioMimetic Pharmaceuticals, Inc. and changed its name to BioMimetic Therapeutics, Inc. in July 2005. BioMimetic Therapeutics, Inc. was founded in 1999 and is headquartered in Franklin, Tennessee.